ConductScience.org, home

Trial · NCT02876835

Outcomes41

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYTime to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)Up to 4.3 person-years for CV follow-up time periodAll Randomized (Intent-to-treat \[ITT\]) Population comprised of all randomized participants. Participants were analyzed according to the treatment to which they were randomized.Events per 100 person yearsNUMBER
PRIMARYMean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52)Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)All Randomized (ITT) Population.Grams per deciliterLEAST_SQUARES_MEAN
SECONDARYTime to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis)Up to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time period
All Randomized (ITT) Population. Only those participants with data available at the indicated time points were analyzed. Additionally, this analysis population was restricted to those with a Baseline eGFR \>=15milliliter per minute (mL/min).
Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time PeriodUp to 4.3 person-years for vital status follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYNumber of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)Up to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.ParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYTime to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Confirmed 40% Decline in eGFR During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population. Only those participants with data available at the indicated time points were analyzed.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Chronic Dialysis During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population. Only those participants with data available at the indicated time points were analyzed.Events per 100 person yearsNUMBER
SECONDARYTime to First Occurrence of Kidney Transplant During CV Events Follow-up Time PeriodUp to 4.3 person-years for CV follow-up time periodAll Randomized (ITT) Population. Only those participants with data available at the indicated time points were analyzed.Events per 100 person yearsNUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02876835/outcomes